{"prompt": "['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', '6.', 'LSR assessment.', '7.', 'Safety Monitoring Questionnaire.', '8.', 'Urine pregnancy test for females of child bearing potential to confirm continued', 'protocol eligibility before application of study drug.', '9.', 'Photographs taken before application of the Study drug.', '10. Administration of study drug to all lesions including those lesions that may be', 'newly developed. If any new lesions are not treatable, this will be documented.', '11.', 'Completion of PERIT assessment by parent or guardian approximately 24 hours', 'following application of the Study drug.', '12. Depending on age of subject, subject or parent/guardian will wash off the Study drug', '16-24 hours post application of Study drug. Patients/guardians may gently remove the', 'Study drug from lesions without the use of a washcloth in problematic areas prior to the', 'expected 16-24 hours if the lesions have already blistered or if the patient is experiencing', 'unmanageable pain. Study drug should not be removed from the additional lesions, where', 'possible, until the expected blistering occurs or the 16-24 hour time point is reached,', 'whichever comes first. If possible patients/guardians should target Study drug removal at', '24 hours.', '13. A follow-up phone call from the investigator or a designated member of the clinical', 'research team will be conducted the following day after each treatment to allow', 'parents/guardians to ask questions and report any concerns, confirm removal of Study', 'drug, and review the completion of the PERIT assessment. Photos will be text or e-mailed', 'by the parent/guardian to the research team for review during the 24-hour phone call.', '4.2.4', 'Evaluation Period / End of Study (~Day 84 or earlier if patient is completely clear', 'of molluscum):', 'Subjects will return to the clinical site for:', '1.', 'Review and recording of any concomitant medications and non-pharmacologic', 'treatments/procedures since previous visit.', '2.', 'Review and recording of any AEs.', 'Page 44']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', '3.', 'Vital signs (heart rate and temperature) obtained at the beginning of visit.', '4.', 'Limited physical examination.', '5.', 'Dermatologic exam (as described in Section 4.2.1) and counts of treated and', 'untreated lesions.', '6.', 'LSR, CDLQI and Safety Monitoring assessments.', '7.', 'Urine pregnancy test for females of childbearing potential.', '8.', 'Photographs', 'Page 45']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', '5.0', 'PROCEDURES FOR HANDLING ADVERSE EVENTS AND SERIOUS', 'ADVERSE EVENTS', '5.1', 'DEFINITION OF AN ADVERSE EVENT', 'The following definition of adverse event (AE) will be used for this study:', 'Adverse event means any untoward medical occurrence associated with the use', 'of a drug in humans, whether or not considered drug related.', 'An AE can be any unfavorable and unintended sign, symptom, or disease (new or', 'exacerbated) temporally associated with the use of the investigational product,', 'regardless of whether it is considered to be related to the investigational product.', 'The following are examples of AEs:', 'Exacerbation of a chronic or intermittent preexisting condition, including an', 'increase in frequency or intensity of the condition', 'New conditions detected or diagnosed after investigational product administration,', 'even if they were present before the start of the study', 'Signs, symptoms, or the clinical sequelae of a suspected interaction with another', 'medical product', 'Examples of AEs do not include the following:', 'Medical procedures (The medical condition that led to the procedure as the AE', 'should be reported.)', 'Situations that are unwanted by the subject but in which an untoward medical', 'occurrence did not occur, for example social inconvenience after admission to a', 'hospital', 'Anticipated day-to-day fluctuations of a preexisting disease or condition (present', 'or detected before enrollment) that does not worsen overall', 'Page 46']\n\n###\n\n", "completion": "END"}